{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:34:24Z","timestamp":1715128464215},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,7]]},"DOI":"10.7759\/cureus.59839","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T21:18:46Z","timestamp":1715116726000},"source":"Crossref","is-referenced-by-count":0,"title":["Thrombotic Thrombocytopenic Purpura in the Setting of Cirrhosis and Baseline Thrombocytopenia"],"prefix":"10.7759","author":[{"given":"Priyanka","family":"Venkatesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantine","family":"Halkidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes","volume":"2012","author":"George JN","year":"2012","unstructured":"George JN, Al-Nouri ZL. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology Am Soc Hematol Educ Program. 2012, 2012:604-9.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1097\/00062752-200209000-00001","article-title":"ADAMTS13 and TTP","volume":"9","author":"Zheng X","year":"2002","unstructured":"Zheng X, Majerus EM, Sadler JE. ADAMTS13 and TTP. Curr Opin Hematol. 2002, 9:389-94.","journal-title":"Curr Opin Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng XL","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR, et al.. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020, 18:2496-502. 10.1111\/jth.15010","journal-title":"J Thromb Haemost"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully M","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F, et al.. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019, 380:335-46. 10.1056\/NEJMoa1806311","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14230","article-title":"ADAMTS13 test and\/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis","volume":"57","author":"Kim CH","year":"2017","unstructured":"Kim CH, Simmons SC, Williams LA II, Staley EM, Zheng XL, Pham HP. ADAMTS13 test and\/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis. Transfusion. 2017, 57:2609-18. 10.1111\/trf.14230","journal-title":"Transfusion"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker A","year":"2021","unstructured":"Cuker A, Cataland SR, Coppo P, et al.. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021, 137:1855-61. 10.1182\/blood.2020009150","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0152","article-title":"Localization of ADAMTS13 to the stellate cells of human liver","volume":"106","author":"Uemura M","year":"2005","unstructured":"Uemura M, Tatsumi K, Matsumoto M, et al.. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005, 106:922-4. 10.1182\/blood-2005-01-0152","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-01-0006","article-title":"Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis","volume":"99","author":"Uemura M","year":"2008","unstructured":"Uemura M, Fujimura Y, Matsumoto M, et al.. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost. 2008, 99:1019-29. 10.1160\/TH08-01-0006","journal-title":"Thromb Haemost"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071835","article-title":"ADAMTS13, vWF, and endotoxin are interrelated and associated with the severity of liver cirrhosis via hypercoagulability","volume":"11","author":"Takaya H","year":"2022","unstructured":"Takaya H, Namisaki T, Asada S, et al.. ADAMTS13, vWF, and endotoxin are interrelated and associated with the severity of liver cirrhosis via hypercoagulability. J Clin Med. 2022, 11:10.3390\/jcm11071835","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2011.00950.x","article-title":"ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score","volume":"42","author":"Takaya H","year":"2012","unstructured":"Takaya H, Uemura M, Fujimura Y, et al.. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score. Hepatol Res. 2012, 42:459-72. 10.1111\/j.1872-034X.2011.00950.x","journal-title":"Hepatol Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12657","article-title":"Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis","volume":"35","author":"Reuken PA","year":"2015","unstructured":"Reuken PA, Kussmann A, Kiehntopf M, Budde U, Stallmach A, Claus RA, Bruns T. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis. Liver Int. 2015, 35:37-45. 10.1111\/liv.12657","journal-title":"Liver Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10577-y","article-title":"Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome","volume":"17","author":"Simbrunner B","year":"2023","unstructured":"Simbrunner B, Villesen IF, Scheiner B, et al.. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome. Hepatol Int. 2023, 17:1532-44. 10.1007\/s12072-023-10577-y","journal-title":"Hepatol Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi F","year":"2017","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA, et al.. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2017, 15:1448-52. 10.1111\/jth.13716","journal-title":"J Thromb Haemost"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001834","article-title":"Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis","volume":"5","author":"Peyvandi F","year":"2021","unstructured":"Peyvandi F, Cataland S, Scully M, et al.. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv. 2021, 5:2137-41. 10.1182\/bloodadvances.2020001834","journal-title":"Blood Adv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.243","article-title":"Coagulopathy in liver disease: a balancing act","volume":"2015","author":"Kujovich JL","year":"2015","unstructured":"Kujovich JL. Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program. 2015, 2015:243-9. 10.1182\/asheducation-2015.1.243","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v6.i5.160","article-title":"Partial splenic artery embolization in cirrhotic patients","volume":"6","author":"Hadduck TA","year":"2014","unstructured":"Hadduck TA, McWilliams JP. Partial splenic artery embolization in cirrhotic patients. World J Radiol. 2014, 6:160-8. 10.4329\/wjr.v6.i5.160","journal-title":"World J Radiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-210112","article-title":"Vascular complications after splenectomy for hematologic disorders","volume":"114","author":"Crary SE","year":"2009","unstructured":"Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood. 2009, 114:2861-8. 10.1182\/blood-2009-04-210112","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.092460","article-title":"Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up","volume":"99","author":"Kristinsson SY","year":"2014","unstructured":"Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica. 2014, 99:392-8. 10.3324\/haematol.2013.092460","journal-title":"Haematologica"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby E","year":"2005","unstructured":"Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005, 31:456-73. 10.1016\/j.ctrv.2005.05.007","journal-title":"Cancer Treat Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-605493","article-title":"Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality","volume":"125","author":"Goel R","year":"2015","unstructured":"Goel R, Ness PM, Takemoto CM, Krishnamurti L, King KE, Tobian AA. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015, 125:1470-6. 10.1182\/blood-2014-10-605493","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/238369-thrombotic-thrombocytopenic-purpura-in-the-setting-of-cirrhosis-and-baseline-thrombocytopenia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T21:18:50Z","timestamp":1715116730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/238369-thrombotic-thrombocytopenic-purpura-in-the-setting-of-cirrhosis-and-baseline-thrombocytopenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.59839","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,7]]}}}